AbbVie Shares Fall 6% Following Revenue Miss
By Sam Boughedda AbbVie (NYSE:ABBV) shares tumbled 6% Friday following its earnings report before the open, which beat earnings estimates but missed revenue expectations. The...
Buy
or
AbbVie News & Analysis
-
-
AbbVie Tops Q2 EPS by 3c, Maintains FY EPS Guidance
AbbVie (NYSE:ABBV) reported Q2 EPS of $3.37, $0.03 better than the analyst estimate of $3.34. Revenue for the quarter came in at $14.58 billion versus the consensus estimate of $14.67...
-
AbbVie earnings beat, Revenue misses in Q2
Investing.com - AbbVie (NYSE:ABBV) reported on Friday second quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced...
-
AbbVie’s Allergan reaches $2 billion opioid lawsuit settlement – Bloomberg News
(Reuters) – AbbVie Inc’s unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News...
-
Earnings Previews: AbbVie, Chevron, Exxon Mobil, Procter & Gamble
The two largest U.S. oil & gas companies report earnings before markets open Friday along with a pharmaceutical and a consumer staples giant.
-
AbbVie Seeks Approval For Inflammatory Bowel Disease Candidate From U.S. FDA and European Medicines Agency
AbbVie (NYSE: ABBV) has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for Upadacitinib (RINVOQ) for the...
-
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Britain Approves Global Blood Therapeutics' Sickle Cell Treatment U.K.'s Medicines and...
-
13 of our companies report earnings this week. Here's what Wall Street expects
The CNBC Investing Club looks ahead to this week's busy earnings calendar, which includes results from Apple to Qualcomm.
-
Top 5 Things to Watch in Markets in the Week Ahead - Fed Rate Hike, Earnings Flood
By Daniel Shvartsman Investing.com - Central Banks and earnings will continue to dominate the week ahead. After the European Central Bank announced an unexpectedly hawkish 50 basis point...
-
AbbVie Fosters Strategic Alliance to Cure Glaucoma
Biopharmaceutical company AbbVie (NYSE: AABV) recently revealed that it has forged a partnership with eye care solutions provider iSTAR Medical SA to develop and commercialize the latter’s...
-
AbbVie Gets Canadian Regulatory Approval For Inflammatory Arthritis Candidate
The Canadian regulatory authority, Health Canada has approved AbbVie’s (NYSE: ABBV) lead drug RINVOQ (upadacitinib, 15 mg), once-daily selective and reversible JAK inhibitor for the...
-
AbbVie, iSTAR Medical Inks Strategic Alliance For Glaucoma Treatment
AbbVie Inc (NYSE: ABBV) announced a strategic transaction to develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device. This...
-
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
Genmab A/S (NASDAQ: GMAB) has announced that AbbVie Inc (NASDAQ: ABBV) will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous...
-
Senate Finance report says AbbVie shifted profit overseas to cut taxes
By Michael Erman (Reuters) – Drugmaker AbbVie Inc generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim...
-
Senate Report Hits AbbVie's Bermuda Tax Structure for U.S. Humira Sales
Company made most of its overall 2021 sales in the U.S. while recording most of its profits in foreign subsidiaries, leaving it with a tax bill far below the 21% U.S. rate.
-
Genmab's Epcoritamab BLA Application a Positive for AbbVie - Morgan Stanley
By Sam Boughedda Morgan Stanley analyst Terence Flynn told investors in a note Friday that Genmab's (NASDAQ:GMAB) announcement of its intent to submit a biologics license application (BLA)...
-
CHMP recommends approval of AbbVie’s Rinvoq for treatment of nr-asSpA
Currently, Rinvoq approved for use in the EU in patients with moderate to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate to...
-
Tuesday's market bounce allows us to raise some cash to buy in the next downturn
We're raising cash about equal to what we put to work last Friday in three trades when the market was much lower.
-
Why AbbVie Stock Is Trading Higher Today
AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug...
-
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Addex Stops Parkinson's-Associated Dyskinesia Trial Addex Therapeutics Ltd (NASDAQ: ADXN)...
-
Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows
Johnson & Johnson (NYSE: JNJ) and AbbVie Inc (NYSE: ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab...
-
J&J, AbbVie cancer drug significantly slows progression of rare lymphoma: study
By Michael Erman (Reuters) – Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check...
-
Stock Market Today: Dow Ends Brutal April With Big Loss as Tech Tanks
By Yasin Ebrahim Investing.com – The Dow slumped Friday, closing out a brutal month for stocks as wave of big tech earnings this week failed to coax the bulls out of hiding. The Dow Jones...
-
S&P 500 Slumps as Amazon, Apple Trigger Sea of Red on Wall Street
By Yasin Ebrahim Investing.com – The S&P 500 fell Friday, as bearish bets on the tech sector resumed, paced by a rout in Amazon after the e-commerce giant reported its first quarterly loss...
-
Midday Stock Movers: Tesla, Apple, Amazon, Robinhood
By Sam Boughedda Investing.com -- U.S. equities are declining before the weekend, with the NASDAQ down over 1.5% midday. Here's what's moving at the midway point on Friday, April...
-
AbbVie Plunges on Revenue Miss - Imbruvica and Humira Revenue Decline
By Sam Boughedda Investing.com -- AbbVie Inc (NYSE:ABBV) stock is down more than 9% in early Friday trading after the company missed revenue expectations. The company reported...
-
AbbVie Tops Q1 EPS by 2c, Revenue Misses, Offers FY Guidance
AbbVie (NYSE:ABBV) reported Q1 EPS of $3.16, $0.02 better than the analyst estimate of $3.14. Revenue for the quarter came in at $13.54 billion versus the consensus estimate of $13.63...
-
AbbVie earnings beat, Revenue misses in Q1
Investing.com - AbbVie (NYSE:ABBV) reported on Friday first quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced...
-
Amazon Shock, Big Oil Reports, Eurozone GDP - What's Moving Markets
By Geoffrey Smith Investing.com -- Stocks are set to end April on a negative note as disappointing updates from Amazon (NASDAQ:AMZN), Apple (NASDAQ:AAPL) and Intel (NASDAQ:INTC) weigh on...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.01%
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Consumer Services, Basic Materials and Technology sectors propelled shares higher. At the close in NYSE,...
-
AbbVie Selloff a Buying Opportunity According to Wells Fargo
By Sam Boughedda Investing.com -- Shares of AbbVie Inc (NYSE:ABBV) fell 5% in Wednesday's session after the announcement that Vice Chairman and President Michael Severino would be...
-
Midday Stock Movers: Delta, PayPal, AbbVie
By Sam Boughedda Investing.com -- U.S. indices are trading positively Wednesday, with the Nasdaq the biggest mover around lunchtime at +1.45%. Here are the midday movers on Wednesday, April...
-
AbbVie earnings beat, Revenue misses in Q4
Investing.com - AbbVie (NYSE:ABBV) reported on Wednesday fourth quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced...
-
Nasdaq Futures Up 220 Pts; Alphabet's Stellar Results Set Tone
By Peter Nurse Investing.com - U.S. stocks are seen opening higher Wednesday, with the technology-focused Nasdaq index likely to outperform on the back of impressive quarterly earnings...
-
Alphabet, Meta Earnings, OPEC+ Meeting ADP Payrolls - What's Moving Markets
By Geoffrey Smith Investing.com -- The world's largest oil exporters meet to decide production quotas for March. Whether they can live up to them is another matter. Alphabet (NASDAQ:GOOGL)...
-
AbbVie Shares Rise After FDA Approves Arthritis Drug
By Sam Boughedda Investing.com — Shares of AbbVie Inc (NYSE:ABBV) rose 1.8% Friday after the company's arthritis drug was approved by the U.S. Food and Drug Administration. The drug,...
-
Walmart, Home Depot Rise Premarket; Tesla, Pfizer Fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, November 16th. Please refresh for updates. Walmart (NYSE:WMT) stock rose 0.7% after the retail giant raised...
-
Abbvie Jumps After Raising Dividend, Annual Profit Forecast
By Dhirendra Tripathi Investing.com – AbbVie stock (NYSE:ABBV) climbed more than 4% Friday after the drugmaker raised its dividend, and also lifted its outlook for annual profit for...
-
AbbVie earnings, Revenue beat in Q3
Investing.com - AbbVie (NYSE:ABBV) reported on Friday third quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that topped expectations. AbbVie announced earnings per...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
